GoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Rating of “Moderate Buy” by Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been assigned a consensus rating of “Moderate Buy” from the fifteen analysts that are covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $9.36.

A number of research analysts have commented on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 price objective on shares of GoodRx in a research note on Friday, August 16th. Raymond James raised shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price on the stock in a research note on Friday, August 9th. UBS Group dropped their price target on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research note on Friday, August 9th. Finally, Citigroup decreased their target price on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a research report on Friday, August 9th.

Insider Buying and Selling at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 4.17% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Cornercap Investment Counsel Inc. lifted its position in GoodRx by 1.7% during the 2nd quarter. Cornercap Investment Counsel Inc. now owns 75,269 shares of the company’s stock worth $587,000 after buying an additional 1,266 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of GoodRx by 5.1% during the first quarter. California State Teachers Retirement System now owns 70,912 shares of the company’s stock worth $503,000 after purchasing an additional 3,444 shares during the period. US Bancorp DE boosted its holdings in GoodRx by 3.7% in the first quarter. US Bancorp DE now owns 109,818 shares of the company’s stock valued at $780,000 after acquiring an additional 3,877 shares during the last quarter. Beacon Capital Management LLC acquired a new position in GoodRx in the first quarter valued at $28,000. Finally, nVerses Capital LLC bought a new stake in shares of GoodRx in the 3rd quarter valued at $33,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

GoodRx Trading Up 1.1 %

NASDAQ:GDRX opened at $6.19 on Friday. The stock has a fifty day simple moving average of $7.15 and a 200-day simple moving average of $7.54. The company has a market capitalization of $2.35 billion, a PE ratio of -47.62, a price-to-earnings-growth ratio of 4.03 and a beta of 1.37. GoodRx has a 52-week low of $4.14 and a 52-week high of $9.26. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.96.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). The company had revenue of $200.60 million for the quarter, compared to analysts’ expectations of $200.47 million. GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.02 earnings per share. On average, equities research analysts expect that GoodRx will post 0.14 earnings per share for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.